摘要
目的探讨术前紫杉醇周疗的新辅助化疗方案联合胃癌根治术治疗胃癌的临床疗效。方法采用随机对照研究方法,选取2022年6月至2023年6月南阳南石医院收治的胃癌患者120例,随机分为对照组和研究组,各60例。对照组患者给予胃癌根治术,研究组患者术前2周开始行新辅助化疗,采用紫杉醇周疗模式,剂量175 mg/m^(2),连续2周,后行胃癌根治术。对比两组患者Barthel指数、焦虑自评表(SAS)、抑郁自评表(SDS)、视觉模拟评分(VAS)、癌胚抗原、糖类抗原199及总不良反应发生率。结果治疗后,研究组患者Barthel指数高于治疗前和对照组,SAS、SDS评分低于治疗前和对照组(P<0.05);研究组VAS评分和癌胚抗原、糖类抗原199低于治疗前和对照组(P<0.05)。研究组和对照组不良反应发生率比较差异无统计学意义(8.33%vs 6.67%,P>0.05)。结论胃癌患者行术前紫杉醇周疗的新辅助化疗方案及胃癌根治术能够改善患者的焦虑、抑郁状态,提高疗效,且安全性高。
Objective To explore the clinical efficacy of preoperative paclitaxel weekly therapy as neoadjuvant chemotherapy combined with radical surgery for gastric cancer.Methods Using a randomized controlled study method,120 gastric cancer patients admitted to Nanyang Nanshi Hospital from June 2022 to June 2023 were randomly divided into control group and study group,with 60 cases in each group.The patients in control group were treated with gastric cancer radical surgery,while the study group patients received neoadjuvant chemotherapy 2 weeks before surgery,using a paclitaxel weekly therapy mode with a dose of 175 mg/m^(2) for 2 consecutive weeks,followed by gastric cancer radical surgery.The Barthel index,self-rating anxiety scale(SAS),self-rating depression scale(SDS),visual analog scale(VAS),carcinoembryonic antigen,carbohydrate antigen199 and total adverse reaction rate were compared between two groups.Results After treatment,the Barthel index was higher,while the SAS and SDS scores were lower of patients in the study group than those before treatment and control group(P<0.05).VAS score,carcinoembryonic antigen,and carbohydrate antigen 199 in the study group were lower than those before treatment and the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group and the control group(8.33%vs 6.67%,P>0.05).Conclusion Preoperative paclitaxel weekly therapy as neoadjuvant chemotherapy combined with radical surgery for gastric cancer can improve the anxiety and depression status of patients and increase the overall effective rate.
作者
梁博
闻朋浩
朱敏敏
LIANG Bo;WEN Penghao;ZHU Minmin(Nanyang Nanshi Hospital,Nanyang,Henan 473000,China)
出处
《中国临床研究》
CAS
2024年第2期212-215,222,共5页
Chinese Journal of Clinical Research
关键词
胃癌
紫杉醇
新辅助化疗
胃癌根治术
癌胚抗原
糖类抗原199
Gastric cancer
Paclitaxel
Neoadjuvant chemotherapy
Radical gastrectomy
Carcinoembryonic antigen
Carbohydrate antigen 199
